Emerging Markets Earnings Roundup: Pfizer (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Pfizer considers the structure of its pharma operations in emerging markets as the dust begins to settle from its spin-off of its animal health business and the sale of its nutrition business.
You may also be interested in...
Pfizer Suffers Grim Q3, But Management Points To Future Growth Drivers
Pfizer’s revenues fell 16% in the third quarter, as the pharma giant absorbed exclusivity losses including the loss of Lipitor, but management tried its best to highlight long-term growth drivers during a Nov. 1 conference call.
Pfizer Moo’ved To Split Off Zoetis Business By July 2013
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.
Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies